Unravelling the Epigenome of Myelodysplastic Syndrome: Diagnosis, Prognosis, and Response to Therapy
Myelodysplastic syndrome (MDS) is a malignancy that disrupts normal blood cell production and commonly affects our ageing population. MDS patients are diagnosed using an invasive bone marrow biopsy and high-risk MDS patients are treated with hypomethylating agents (HMAs) such as decitabine and azacy...
Main Authors: | Danielle R. Bond, Heather J. Lee, Anoop K. Enjeti |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-10-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/11/3128 |
Similar Items
-
The Role of Non-Coding RNAs in Myelodysplastic Neoplasms
by: Vasileios Georgoulis, et al.
Published: (2023-09-01) -
Sleep Deprivation and the Epigenome
by: Marie E. Gaine, et al.
Published: (2018-02-01) -
Epigenomic Dysregulation in Schizophrenia: In Search of Disease Etiology and Biomarkers
by: Behnaz Khavari, et al.
Published: (2020-08-01) -
The myelodysplastic syndromes: diagnosis, prognosis and therapy
by: Cristina Clissa, et al.
Published: (2013-03-01) -
Myelodysplastic syndrome: classification and prognostic systems
by: Rosangela Invernizzi, et al.
Published: (2011-12-01)